nivolumab
Opdivo
Pharmaceutical company: Bristol-Myers Squibb
NEW INDICATION & DOSAGE
Neoadjuvant treatment of resectable non–small-cell lung cancer (tumors of at least 4 cm or node-positive) in combination with platinum-doublet chemotherapy
Adults: 360-mg IV infusion followed by platinum-doublet chemotherapy on the same day every 3 weeks for 3 cycles.
Released: May 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
sirolimus
Hyftor
Pharmaceutical company: Nobelpharma America
NEW FORM
Topical gel:2 mg/g
INDICATION & DOSAGE
Facial angiofibroma associated with tuberous sclerosis
Adults and children age 12 and older: Apply to facial skin b.i.d. Maximum dose, 800 mg (2.5 cm).
Children ages 6 to 11: Apply to facial skin b.i.d. Maximum dose, 600 mg (2 cm).
Adjust-a-dose: Reevaluate need for the drug if symptoms don’t improve within 12 weeks of treatment.
Released: May 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
upadacitinib
Rinvoq
Pharmaceutical company: AbbVie
NEW INDICATION & DOSAGE
Moderate to severe active ulcerative colitis after inadequate response or intolerance to one or more TNF blockers
Adults: 45 mg PO once daily for 8 weeks, followed by a maintenance dose of 15 mg once daily. May increase maintenance dose to 30 mg once daily for patients with refractory, severe, or extensive disease. If patient response to 30-mg dose is inadequate, discontinue the drug. Use the lowest effective dose needed to maintain response.
Adjust-a-dose: If the patient has severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2), mild to moderate hepatic impairment (Child-Pugh class A or B), or is taking a strong CYP3A4 inhibitor, give induction dose, 30 mg once daily for 8 weeks; then maintenance dose, 15 mg once daily.
Released: May 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer